EP Patent

EP4572753A2 — Adagrasib solid pharmaceutical compositions

Assigned to Mirati Therapeutics Inc · Expires 2025-06-25 · 1y expired

What this patent protects

Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer.

USPTO Abstract

Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4572753A2
Jurisdiction
EP
Classification
—
Expires
2025-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.